Doses as study findings, not guidance
Thymulin Dosage: What Was Administered in the Research, and to Whom
There is no established human dose. The literature reports amounts only as study findings — recorded here as such, never as a protocol to follow.
Start here
There is no established human dose for thymulin. It is a research peptide, not an approved medicine, so this page reports only what was given in studies — to which species, at what amount, by what route — and nothing on this page is guidance for a person. In animals the amounts are tiny: nanograms to low micrograms (a nanogram is a billionth of a gram). The human half-life — how long it lasts in the body — has not been pinned down in the public literature, which is exactly why researchers built gene-therapy versions to keep it circulating. Read every number below as a fact about a study, not an instruction.
Thymulin Peptide Dosage in the Research Literature
Reported thymulin peptide dosage figures come only from research, and they are small. Rodent anti-inflammatory and analgesia work used nanogram-to-low-microgram amounts per animal — on the order of 0.1-1 microgram intracerebroventricularly, or roughly 1-1000 ng intraperitoneally, varying by model [8]. In mouse systemic-inflammation models, the peptide was given intraperitoneally, often daily or every other day [11]. One radioprotection study in mice used daily subcutaneous serum thymic factor at 3-100 microg/day against lethal total-body irradiation [17]. A rat pulmonary-hypertension model used roughly 100 ng/kg/day subcutaneously per its source [8]. These are study-reported amounts in animals, not human protocols [6].
What doses of thymulin were used in animal studies?
Reported animal doses range from a few nanograms to low micrograms per animal, depending on the model and route. Examples from the literature: about 0.1-1 microgram intracerebroventricularly and roughly 1-1000 ng intraperitoneally in rodent CNS and inflammation work [8]; 3-100 microg/day subcutaneously in a mouse radioprotection study [17]; and 4.4-444.4 ng/kg intravenously (with 1-1000 ng/mL in vitro) in a boar steroidogenesis study [14]. These are study-reported amounts, not protocols to follow [6].
The routes thymulin has been delivered by in research
Thymulin and its constructs have been delivered by a range of routes in research, each tied to the model. The routes studied include intraperitoneal, subcutaneous, intracerebroventricular, intratracheal (for inhaled gene therapy), intramuscular (for a gene-therapy vector), topical (in a zinc-thymulin pilot), and plain cell culture in vitro [8][16]. The choice tracks the question: CNS analgesia work used intracerebroventricular delivery [8], the asthma reversal used a single intratracheal nanoparticle dose [16], and the neuroendocrine gene therapy used vector delivery [15].
How is thymulin administered in research?
In research, thymulin is administered by injection or delivered as a gene-therapy construct, depending on the model. Native peptide has been given intraperitoneally, subcutaneously, and intracerebroventricularly in animals [8]; gene-therapy approaches used intratracheal nanoparticles [16] and intramuscular or intracerebral adenovectors [15]. A small pilot explored a topical zinc-thymulin preparation [6]. As a research chemical it is not intended for human consumption, and there is no approved administration route for people [6].
Is thymulin taken as an injection?
In research, native thymulin has been given by injection — intraperitoneal and subcutaneous routes in animal models, among others [8]. As a research chemical, thymulin is not intended for human consumption, and there is no approved injectable product [6]. Any injection described in the literature is an experimental procedure in a study species, not a human practice.
What is the dosage of thymulin peptide?
There is no established human dose of thymulin peptide. Research doses appear only as study findings — typically nanogram-to-low-microgram amounts per animal by injection in rodents [8]. Because thymulin's activity is strictly zinc-dependent, reported effects are also entangled with zinc status, which complicates dose interpretation [6]. None of these figures is human dosing guidance [6].
What Is the Half-Life of Thymulin?
The human half-life of thymulin is not well characterized in the public literature. As a small peptide, native thymulin has a short circulating half-life, but a precise human pharmacokinetic figure is not established [7]. This gap is itself informative: gene-therapy approaches were developed specifically to sustain circulating thymulin levels, which would be unnecessary if the native peptide persisted [7][15]. Treat any single quoted half-life number with caution unless it names its species and method.
Is There a Thymulin Supplement?
Thymulin is not a dietary supplement; it is a research peptide with no approved consumer form [6]. The nearest supplementation context is zinc, because zinc status governs thymulin activity in research models — in mild human zinc deficiency, thymulin activity fell and was corrected by zinc repletion [5]. That makes zinc the relevant variable, not a stand-in for thymulin itself [3]. Consumer framing of a "thymulin supplement" should be read against the fact that the peptide is unapproved and largely studied in animals [6].
Stability: the zinc ion is part of the molecule
Thymulin's activity is inseparable from its bound zinc. Zinc chelation — for instance by EDTA or Chelex — abolishes activity, and the apopeptide stays inactive until zinc is restored [1][18]. In other words, the peptide's functional integrity depends on the metal being present, which is why the zinc-dependent activation is treated as a property of the molecule itself rather than an add-on. This is a research-handling observation, not a storage instruction for any consumer product [6].